Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  2/2/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 2/2/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  2/2/2018
University of California San Francisco Medical Center-Mount Zion
mi
from
San Francisco, CA
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 2/2/2018
University of California San Francisco Medical Center-Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  2/2/2018
Sarah Cannon Research Institute Research Center
mi
from
Denver, CO
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 2/2/2018
Sarah Cannon Research Institute Research Center
mi
from
Denver, CO
Click here to add this to my saved trials
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  2/2/2018
Northwestern Memorial Hospital
mi
from
Chicago, IL
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 2/2/2018
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  2/2/2018
University of Chicago Medical Center
mi
from
Chicago, IL
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 2/2/2018
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  2/2/2018
Horizon Oncology Center
mi
from
Lafayette, IN
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 2/2/2018
Horizon Oncology Center
mi
from
Lafayette, IN
Click here to add this to my saved trials
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  2/2/2018
John Hopkins
mi
from
Baltimore, MD
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 2/2/2018
John Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  2/2/2018
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 2/2/2018
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  2/2/2018
Washington University School of Medicine St. Louis
mi
from
Saint Louis, MO
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 2/2/2018
Washington University School of Medicine St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  2/2/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 2/2/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  2/2/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 2/2/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  2/2/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 2/2/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors
An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer
Status: Enrolling
Updated:  2/2/2018
NYU Perlmutter Cancer Center
mi
from
New York, NY
An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors
An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer
Status: Enrolling
Updated: 2/2/2018
NYU Perlmutter Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Status: Enrolling
Updated:  2/2/2018
Massachusetts General Hospital
mi
from
Boston, MA
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Status: Enrolling
Updated: 2/2/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor
Status: Enrolling
Updated:  2/2/2018
Clinical Research Facility
mi
from
Louisville, KY
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor
Status: Enrolling
Updated: 2/2/2018
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor
Status: Enrolling
Updated:  2/2/2018
Clinical Research Facility
mi
from
Morristown, NJ
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor
Status: Enrolling
Updated: 2/2/2018
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor
Status: Enrolling
Updated:  2/2/2018
Clinical Research Facility
mi
from
Armonk, NY
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor
Status: Enrolling
Updated: 2/2/2018
Clinical Research Facility
mi
from
Armonk, NY
Click here to add this to my saved trials
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated:  2/2/2018
Northwestern University, Northwestern Medical Faculty Foundation
mi
from
Chicago, IL
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated: 2/2/2018
Northwestern University, Northwestern Medical Faculty Foundation
mi
from
Chicago, IL
Click here to add this to my saved trials
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated:  2/2/2018
Hematology-Oncology Associates of Illinois
mi
from
Chicago, IL
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated: 2/2/2018
Hematology-Oncology Associates of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated:  2/2/2018
Midwest Center for Hematology/Oncology
mi
from
Joliet, IL
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated: 2/2/2018
Midwest Center for Hematology/Oncology
mi
from
Joliet, IL
Click here to add this to my saved trials
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated:  2/2/2018
Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields
mi
from
Olympia Fields, IL
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated: 2/2/2018
Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields
mi
from
Olympia Fields, IL
Click here to add this to my saved trials
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated:  2/2/2018
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated: 2/2/2018
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
A Phase II, Open-label, Multicentre Study of PM060184 in Patients With Advanced Colorectal Cancer After Standard Treatment.
Status: Enrolling
Updated:  2/2/2018
US017
mi
from
Los Angeles, CA
Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
A Phase II, Open-label, Multicentre Study of PM060184 in Patients With Advanced Colorectal Cancer After Standard Treatment.
Status: Enrolling
Updated: 2/2/2018
US017
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
A Phase II, Open-label, Multicentre Study of PM060184 in Patients With Advanced Colorectal Cancer After Standard Treatment.
Status: Enrolling
Updated:  2/2/2018
CA001
mi
from
Toronto,
Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
A Phase II, Open-label, Multicentre Study of PM060184 in Patients With Advanced Colorectal Cancer After Standard Treatment.
Status: Enrolling
Updated: 2/2/2018
CA001
mi
from
Toronto,
Click here to add this to my saved trials
The Effect of Berries on Lung Cancer Tumors
Berry Interventional Trial (BIT) in Resected Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/3/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
The Effect of Berries on Lung Cancer Tumors
Berry Interventional Trial (BIT) in Resected Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/3/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma
Phase I/II Trial of Mithramycin in Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWSFLI1 Fusion Transcript (Phase II)
Status: Enrolling
Updated:  2/3/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma
Phase I/II Trial of Mithramycin in Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWSFLI1 Fusion Transcript (Phase II)
Status: Enrolling
Updated: 2/3/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors
Phase I Study of PTK/ZK in Combination With Pemetrexed Disodium (ALIMTA)
Status: Enrolling
Updated:  2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors
Phase I Study of PTK/ZK in Combination With Pemetrexed Disodium (ALIMTA)
Status: Enrolling
Updated: 2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Studying the Effect of Freeze-Dried Table Grape Powder on Blood Estrogen Levels in Postmenopausal Women
Evaluation of the Aromatase Inhibition Potential of Standardized Grape Extract
Status: Enrolling
Updated:  2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Studying the Effect of Freeze-Dried Table Grape Powder on Blood Estrogen Levels in Postmenopausal Women
Evaluation of the Aromatase Inhibition Potential of Standardized Grape Extract
Status: Enrolling
Updated: 2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors
Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors
Status: Enrolling
Updated:  2/5/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors
Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors
Status: Enrolling
Updated: 2/5/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Physical Activity in Public Housing - II
Perceptions of School, Recreation, and Transportation Environments Among African American Families in Public Housing--II
Status: Enrolling
Updated:  2/5/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Physical Activity in Public Housing - II
Perceptions of School, Recreation, and Transportation Environments Among African American Families in Public Housing--II
Status: Enrolling
Updated: 2/5/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer
White Wine for Appetite Loss: A Randomized, Controlled, Non-Blinded Trial
Status: Enrolling
Updated:  2/5/2018
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer
White Wine for Appetite Loss: A Randomized, Controlled, Non-Blinded Trial
Status: Enrolling
Updated: 2/5/2018
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer
White Wine for Appetite Loss: A Randomized, Controlled, Non-Blinded Trial
Status: Enrolling
Updated:  2/5/2018
Mayo Clinic Florida
mi
from
Jacksonville, FL
White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer
White Wine for Appetite Loss: A Randomized, Controlled, Non-Blinded Trial
Status: Enrolling
Updated: 2/5/2018
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer
White Wine for Appetite Loss: A Randomized, Controlled, Non-Blinded Trial
Status: Enrolling
Updated:  2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer
White Wine for Appetite Loss: A Randomized, Controlled, Non-Blinded Trial
Status: Enrolling
Updated: 2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer
White Wine for Appetite Loss: A Randomized, Controlled, Non-Blinded Trial
Status: Enrolling
Updated:  2/5/2018
Geisinger Medical Center
mi
from
Danville, PA
White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer
White Wine for Appetite Loss: A Randomized, Controlled, Non-Blinded Trial
Status: Enrolling
Updated: 2/5/2018
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Phase I Trial of The Combination of Vismodegib and Sirolimus
Status: Enrolling
Updated:  2/5/2018
Mayo Clinic Campus in Arizona
mi
from
Scottsdale, AZ
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Phase I Trial of The Combination of Vismodegib and Sirolimus
Status: Enrolling
Updated: 2/5/2018
Mayo Clinic Campus in Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Phase I Trial of The Combination of Vismodegib and Sirolimus
Status: Enrolling
Updated:  2/5/2018
Mayo Clinic Campus in Florida
mi
from
Jacksonville, FL
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Phase I Trial of The Combination of Vismodegib and Sirolimus
Status: Enrolling
Updated: 2/5/2018
Mayo Clinic Campus in Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Phase I Trial of The Combination of Vismodegib and Sirolimus
Status: Enrolling
Updated:  2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
Phase I Trial of The Combination of Vismodegib and Sirolimus
Status: Enrolling
Updated: 2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Quality of Life Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Status: Enrolling
Updated:  2/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Quality of Life Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Status: Enrolling
Updated: 2/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
1303GCC: Phase II Study of Trastuzumab and Pertuzumab Alone and in Combination With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced and/or Metastatic Breast Carcinoma
Status: Enrolling
Updated:  2/5/2018
University of Maryland/Marlene and Stewart Greenebaum Cancer Center
mi
from
Baltimore, MD
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
1303GCC: Phase II Study of Trastuzumab and Pertuzumab Alone and in Combination With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced and/or Metastatic Breast Carcinoma
Status: Enrolling
Updated: 2/5/2018
University of Maryland/Marlene and Stewart Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Status: Enrolling
Updated:  2/5/2018
Mayo Clinic Campus in Arizona
mi
from
Scottsdale, AZ
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Status: Enrolling
Updated: 2/5/2018
Mayo Clinic Campus in Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Status: Enrolling
Updated:  2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Status: Enrolling
Updated: 2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies
Status: Enrolling
Updated:  2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies
Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies
Status: Enrolling
Updated: 2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma
Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma
Status: Enrolling
Updated:  2/5/2018
Dana-Farber Cancer Insititue
mi
from
Boston, MA
Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma
Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma
Status: Enrolling
Updated: 2/5/2018
Dana-Farber Cancer Insititue
mi
from
Boston, MA
Click here to add this to my saved trials
Preoperative Acetaminophen and Carbohydrate Loading
Impact of Preoperative Acetaminophen and Carbohydrate Loading to on Pain and Functional Status in Patients Undergoing Mohs Micrographic Surgery for Non-melanoma Skin Cancers
Status: Enrolling
Updated:  2/5/2018
Tufts Dermatology
mi
from
Boston, MA
Preoperative Acetaminophen and Carbohydrate Loading
Impact of Preoperative Acetaminophen and Carbohydrate Loading to on Pain and Functional Status in Patients Undergoing Mohs Micrographic Surgery for Non-melanoma Skin Cancers
Status: Enrolling
Updated: 2/5/2018
Tufts Dermatology
mi
from
Boston, MA
Click here to add this to my saved trials
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/5/2018
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/5/2018
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/5/2018
UCI Medical Center-Chao Family Comprehensive (Site 210)
mi
from
Orange, CA
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/5/2018
UCI Medical Center-Chao Family Comprehensive (Site 210)
mi
from
Orange, CA
Click here to add this to my saved trials
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  2/5/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 2/5/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
Phase I/II Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS) for the Treatment of Metastatic Spine Disease
Status: Enrolling
Updated:  2/6/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
Phase I/II Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS) for the Treatment of Metastatic Spine Disease
Status: Enrolling
Updated: 2/6/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Screening for Familial Colorectal Cancer (CRC) Patients
Screening and Risk Communication for First Degree Relatives of Colorectal Cancer Patients
Status: Enrolling
Updated:  2/6/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Screening for Familial Colorectal Cancer (CRC) Patients
Screening and Risk Communication for First Degree Relatives of Colorectal Cancer Patients
Status: Enrolling
Updated: 2/6/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Stool Testing for Pancreatic Cancer
Detection of Pancreatic Cancer and Pre-cancer by Stool DNA Testing: A Feasibility Study
Status: Enrolling
Updated:  2/6/2018
Columbia University Medical Center
mi
from
New York, NY
Stool Testing for Pancreatic Cancer
Detection of Pancreatic Cancer and Pre-cancer by Stool DNA Testing: A Feasibility Study
Status: Enrolling
Updated: 2/6/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials